TP53 and myelodysplastic syndrome: Therefore, it is crucial to differentiate these patients from those with MDS with mutated TP53; (4) In MDS-IB2 patients, further distinction is needed for those with MDS-related gene mutations and cytogenetic abnormalities due to differing prognoses; (5) Within the ICC framework, BM fibrosis’ survival impact was less pronounced, prompting the refinement of the two-class system.